Actively Recruiting
Evaluating Dato-DXd Treatment in Advanced Hormone Receptor-Positive, HER2 IHC 0 Breast Cancer Not Responsive to Endocrine Therapy
Led by AstraZeneca · Updated on 2026-10-02
100
Participants Needed
40
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying Dato-DXd, a drug being evaluated for treating patients with metastatic hormone receptor-positive, HER2 IHC 0 breast cancer that cannot be treated with surgery and is resistant to hormone therapy. This Phase IIIb, single-arm, open-label, multinational study aims to assess the efficacy and safety of Dato-DXd in this group of patients. The study is sponsored by AstraZeneca and focuses on patients who have progressed beyond endocrine therapy, with a goal to monitor progression-free survival and other outcomes. Participants will receive Dato-DXd at a dose of 6 mgkg given by intravenous infusion every 3 weeks, with a maximum dose of 540 mg for patients weighing 90 kg or more. Treatment continues until the disease progresses, unacceptable side effects occur, or the participant chooses to stop. Tumor biopsies will be collected before treatment and, if possible, at progression to analyze HER2 and TROP2 expression and other biomarkers. Imaging scans will be performed every 8 weeks during the first 48 weeks and then every 12 weeks thereafter until disease progression. Throughout the study, participants will undergo regular tumor imaging and provide blood samples for liquid biopsies to evaluate biomarkers linked to treatment response and resistance. Safety will be monitored closely, including assessments for oral mucositis, eye events, and other adverse events. The main outcome measured is progression-free survival up to about 24 months from the first dose. Participants are expected to be followed for up to around 30 months, with the study ending in early 2028.
CONDITIONS
Brief Title
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here